A perspective current and past modes of inhalation therapy.

Olga Martínez-Augustin, Abdelali Daddaoua, Kelsey Aguirre Schilder, Ana Rosa Márquez Blesa, José Canto Mangana, José Ignacio Bretones-Pedrinaci, Fermín Sánchez de Medina

Journal: Microbial biotechnology 2024;17(2):e14419

PMID: 38387963

Free Full Text on PubMed Central View on PubMed

Abstract

Inhalation is the preferred route of delivery for anti-asthma and chronic obstructive pulmonary disease (COPD) drugs. The use of this route has demonstrated efficacy in these and other conditions, it offers rapid onset of action, and is associated with minimal systemic exposure, thereby reducing the risk of adverse effects. Therefore, the current brief covers an interesting collection of inhaler action modes, shedding light on their molecular mechanisms and clinical applications for anti-asthma, COPD and antibacterial inhalation therapy. Hence, not only enriches our understanding of inhalation therapy molecular intricacies but also provides a comprehensive overview of the evolving landscape in clinical and antibacterial inhalation therapy. In doing so, it underscores the pivotal role of microbiology and biotechnology in advancing therapeutic approaches that harness the power of inhalation.

Address: Department of Biochemistry and Molecular Biology II, Pharmacy School, University of Granada, Granada, Spain.; Pharmacy Services, A.S. Hospital de Poniente de Almería, Almería, Spain.; Department of Biochemistry and Molecular Biology II, Pharmacy School, University of Granada, Granada, Spain.; Pharmacy Services, A.S. Hospital de Poniente de Almería, Almería, Spain.; Department of Pharmacology, School of Pharmacy, University of Granada, Granada, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.; Instituto de Investigación Biosanitaria (IBS), Granada, Spain.; Department of Biochemistry and Molecular Biology II, Pharmacy School, University of Granada, Granada, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.; Instituto de Investigación Biosanitaria (IBS), Granada, Spain.; Institute of Nutrition and Food Technology 'José Mataix', Center of Biomedical Research, University of Granada, Granada, Spain.; Department of Biochemistry and Molecular Biology II, Pharmacy School, University of Granada, Granada, Spain.; Instituto de Investigación Biosanitaria (IBS), Granada, Spain.; Institute of Nutrition and Food Technology 'José Mataix', Center of Biomedical Research, University of Granada, Granada, Spain.

DOI: 10.1111/1751-7915.14419